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a b s t r a c t
West Nile virus (WNV) employs several different strategies to escape the innate immune response.
We have previously demonstrated that the WNV NS1 protein interferes with signal transduction from
Toll-like receptor 3 (TLR3). NS1 is a glycoprotein that can be found intracellularly or associated with the
plasma membrane. In addition, NS1 is secreted to high levels during ﬂavivirus infections. We
investigated whether the secreted form of NS1 inhibits innate immune signaling pathways in uninfected
cells. Secreted NS1 (sNS1) was puriﬁed from supernatants of cells engineered to express the protein.
Puriﬁed sNS1 associated with and repressed TLR3-induced cytokine production by HeLa cells, and
inhibited signaling from TLR3 and other TLRs in bone marrow-derived macrophages and dendritic cells.
Footpad administration of sNS1 showed the protein associated predominantly with macrophages and
dendritic cells in the draining lymph node. Additionally, sNS1 signiﬁcantly reduced TLR3 signaling and
WNV replicon particle-mediated cytokine transcription in popliteal lymph nodes.
& 2014 Elsevier Inc. All rights reserved.
Introduction
West Nile virus is a member of the family Flaviviridae whose
clinically important members include yellow fever virus, dengue
virus, and Japanese encephalitis virus. WNV exists in a transmis-
sion cycle between birds and mosquitoes, where humans are
incidental hosts. Early WNV replication in mouse models of
disease occurs in keratinocytes (Brown et al., 2007; Lim et al.,
2011) and skin-resident dendritic cells (DCs), including Langerhans
DCs (Wu et al., 2000). Infection initiates migration of Langerhans
DCs to draining lymph nodes where further viral expansion occurs
concurrently with activation of the immune response (Byrne et al.,
2001; Johnston et al., 2000). Upon entry into the bloodstream,
WNV infects peripheral tissues such as the spleen and the kidneys.
In certain animals, the virus is able to invade the central nervous
system and infect neurons of the brain stem, hippocampus, and
spinal cord.
The innate immune response is the ﬁrst line of defense against
invading pathogens and can signiﬁcantly inﬂuence viral pathogen-
esis as well as shape the ensuing adaptive immune response.
In recent years, signiﬁcant progress has been made in identifying
virus interactions with the innate immune system.
One arm of the innate immune response involves the recogni-
tion of pathogen-associated molecular patterns (PAMPs), eliciting
proinﬂammatory cytokine responses and the production of type I
interferon. Several different pattern recognition receptors (PRRs)
have been implicated in the recognition of ﬂavivirus infections
such as the RNA helicases RIG-I, Mda-5, and a variety of different
TLRs (Dafﬁs et al., 2008; Diebold et al., 2004; Fredericksen et al.,
2008; Loo et al., 2008; Lund et al., 2004; Nasirudeen et al., 2011;
Silva et al., 2007; Town et al., 2009; Tsai et al., 2009; Wang et al.,
2006, 2004; Welte et al., 2009).
Our previous work has demonstrated that TLR3 signaling is
inhibited in WNV infected cells (Scholle and Mason, 2005) and this
inhibition is due to expression of the NS1 protein (Wilson et al.,
2008). NS1 is a glycoprotein that is required for RNA replication
where it participates in early RNA synthesis (Khromykh et al.,
1999; Lindenbach and Rice, 1997; Westaway et al., 1997; Youn
et al., 2012). In the infected cell, NS1 is translocated into the lumen
of the ER and forms detergent stable, but heat labile, dimers.
Additionally, NS1 is secreted from infected cells to high levels
(Chung and Diamond, 2008; Macdonald et al., 2005), and this
soluble form is detectable as a hexamer (Flamand et al., 1999).
Secreted NS1 (sNS1) is known to associate with a number of
different cell types in vitro (Avirutnan et al., 2007) and in vivo
(Alcon-LePoder et al., 2005) and for both WNV sNS1 and dengue
virus sNS1, binding to uninfected endothelial cells is dependent on
interactions with sulfated glycosaminoglycans (Avirutnan et al.,
2007; Youn et al., 2010).
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Given the documented interactions of sNS1 with uninfected
cells and our previous data showing NS1-mediated inhibition of
TLR3 signaling, we hypothesized that sNS1 can modulate innate
immune responses in naïve cells. Our data shows sNS1 puriﬁed
from cell culture supernatants can inhibit TLR signaling in differ-
ent cell types of both human and murine origin and impairs
cytokine production in response to WNV and replicon particle
infection. Importantly, sNS1 was also able to modulate cytokine
secretion in response to both TLR3-stimulation and WNV VRP
infection in vivo. This is the ﬁrst evidence of a secreted RNA virus
protein capable of modulating TLR signaling.
Results
Secreted NS1 associates with naïve cells and inhibits TLR3 signaling
Initial studies were aimed at determining the ability of cells to
associate with NS1 secreted from HeLa cells, which stably express
the WNV replicon (HeLa rep cells) (Scholle and Mason, 2005).
Uninfected, i.e., replicon-free Huh-7 cells were seeded onto cham-
ber slides and then transfected to express a red ﬂuorescent protein
(RFP). After transfection the cells were washed extensively to
remove all traces of transfection reagent. At this point the HeLa
rep cells were added to the uninfected Huh-7 cells and co-cultured
for 16 h. After incubation, the slides were ﬁxed and permeabilized
before being stained with a WNV-speciﬁc hyperimmune serum and
an FITC–tagged secondary antibody. Results showed association of a
WNV protein (green) with the uninfected cells (red) (Supplemental
Fig. 1). Therefore, within 16 h, uninfected cells associated with a
potentially secreted WNV non-structural protein. To next address
whether WNV infected cells are able to inﬂuence TLR3 signaling in
neighboring uninfected cells, IFNβ promoter induction was mea-
sured by reporter assay in HeLa cells that were incubated in the
presence of HeLa rep cells. Uninfected HeLa cells were transfected
with a reporter construct in which luciferase (Luc) expression is
controlled by the IFNβ promoter, as described previously (Wilson
et al., 2008). The transfected cells were then incubated for 16 h with
other uninfected HeLa cells or with HeLa rep cells. Poly(I:C) was
then added directly to the co-cultures to stimulate TLR3 signaling
and 4 h later cell lysates were harvested and analyzed for Luc
activity. Strong IFNβ promoter-driven Luc expression was detected
in the HeLa cells co-cultured with uninfected HeLa cells, whereas
reporter-transfected HeLa cells cultured with HeLa rep cells showed
a signiﬁcantly diminished response to TLR3 stimulation (Fig. 1A).
These data show WNV replicon infected cells can modulate TLR3
responses in neighboring uninfected cells. To investigate whether
this phenomenon was cell contact dependent or mediated by a
soluble factor, the experiments were repeated by incubating
reporter-transfected HeLa cells with clariﬁed supernatants har-
vested from HeLa rep cells. Poly(I:C)-induced Luc expression was
greatly reduced in HeLa cells incubated with HeLa rep supernatants,
whereas Luc expression was unabated in the HeLa cells incubated
with supernatants from uninfected HeLa cells. These data conﬁrm
that a soluble factor is sufﬁcient for TLR3 inhibition (Fig. 1B).
Though NS1 is the only non-structural protein known that is
secreted from WNV-infected cells, the HeLa rep cell line expresses
all non-structural (NS) proteins. In order to demonstrate that the
observed inhibitory effect was sNS1-dependent, a 293T cell line
that expresses NS1 from a stably integrated lentivirus vector
(293T-NS1) was generated. Western blots of clariﬁed supernatants
harvested from 293T-NS1 cells conﬁrmed NS1 secretion from
these cells (data not shown). Previous studies have reported the
binding and rapid endocytosis of sNS1 by naïve cells (Alcon-
LePoder et al., 2005; Avirutnan et al., 2007). In agreement with
these studies, the initial characterization of 293T-NS1 supernatants
also showed sNS1 association with naïve HeLa cells. Clariﬁed
supernatants from the 293T-NS1 cell line or from the 293T
lentivirus vector control cell line (293T-Ctrl) were added to HeLa
cells and 16 h later, the cells were analyzed by immunoﬂuorescence
using an NS1-speciﬁc antibody. Microscopic analysis revealed
punctate, NS1-speciﬁc staining in cells incubated with sNS1-
containing supernatants (Fig. 1C). Additionally, an NS1-speciﬁc band
was detected by Western blot analysis of whole cell extracts of HeLa
cells incubated with 293T-NS1 supernatants (Fig. 1D). To determine
whether sNS1 simply binds to the cells or becomes internalized,
permeabilized and non-permeabilized cells, incubated with super-
natants from either 293T-NS1 or 293T-Ctrl, were compared by ﬂow
cytometry. Within 6 h of sNS1 addition, NS1 positive staining was
stronger in permeabilized cells than in non-permeabilized cells,
indicating that internalization of sNS1 occurred rapidly (Fig. 1E).
NS1 positive staining was still detectable after 24 h and showed an
even higher level of internalized sNS1, suggesting no appreciable
degradation of the protein by HeLa cells was occurring. Next, sNS1
containing supernatants from 293T-NS1 cells were examined for
their ability to inhibit TLR3 signaling in the absence of other WNV
NS proteins. HeLa cells were transfected with the IFNβ–Luc reporter
construct and incubated with supernatants from either 293T-NS1
cells or 293T-Ctrl cells for 16 h before stimulation with poly(I:C).
IFNβ promoter activation was signiﬁcantly diminished in cells
incubated with sNS1-containing supernatants as compared to cells
incubated with 293T-Ctrl supernatants (Fig. 1F). Incubation with
sNS1 containing supernatants was not toxic to the cells as con-
ﬁrmed by MTT assay (Supplemental Fig. S2). These results conﬁrm
that the inhibitory effect is dependent on NS1 expression, however,
they do not explicitly demonstrate that sNS1 is directly responsible
for the inhibition.
Association of sNS1 with naïve cells is required for inhibition of TLR3
signaling
Although our data strongly suggest the inhibition of TLR3
signaling is sNS1-dependent, the possibility remained that this
inhibitory effect is attributable to another secreted factor induced
by intracellular NS1 rather than sNS1 directly. To address this
question, we investigated whether direct association of sNS1 with
naïve cells is required for TLR3 signaling inhibition. Secreted NS1
of both dengue and WNV are known to associate with cells via
glycosaminoglycans (GAGs), such as heparan sulfate and chon-
droitin sulfate E (Avirutnan et al., 2007; Youn et al., 2010). Cell
binding by dengue or WNV sNS1 is dependent on the sulfation of
GAG residues, as pretreatment of cells with sodium chlorate, a
chemical used to inhibit GAG sulfation, ablates sNS1-cell binding
(Avirutnan et al., 2007; Youn et al., 2010). To determine if GAG
sulfation was also required for the binding of sNS1 derived from
the 293T-NS1 cell line, supernatants containing sNS1 were col-
lected from 293T-NS1 cells grown in sulfate-free media. HeLa cells
were pretreated with increasing concentrations of sodium chlorate
for 24 h, followed by incubation with sulfate-free, sNS1-containing
supernatants. The cultures were examined periodically during the
sodium chlorate treatment and no cytotoxic effect was observed.
Association of sNS1 with HeLa cells was determined by ﬂow
cytometry and showed sodium chlorate pretreatment inhibited
sNS1 binding to HeLa cells in a concentration dependent manner
(Fig. 2A). To determine how the sodium chlorate treatment would
affect TLR3 signaling inhibition by sNS1-containing supernatants,
HeLa cells were treated with sodium chlorate before incubation
with sulfate-free supernatants. After 8 h of poly(I:C) stimulation,
TLR3 signaling was assessed by measuring IL-6 secretion, as
previously reported (Wilson et al., 2008). Though TLR3 responses
were slightly affected by sodium chlorate alone, the signaling
capacity of the cells was retained and treatment with increasing
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doses of sodium chlorate alleviated sNS1-mediated signaling
inhibition (Fig. 2B). Therefore, the inability of sNS1 to bind directly,
correlated with the restoration of TLR3 signaling by HeLa cells.
Since sNS1-cell binding is required for inhibition of TLR3 signaling,
these data strongly suggest that the inhibitory effect is, in fact,
directly attributable to sNS1.
Puriﬁed sNS1 inhibits TLR3 signaling
To further establish that the observed effects on TLR3 signaling
were sNS1-dependent, sNS1 was puriﬁed from the supernatants of
the 293T-NS1 cell line by immunoafﬁnity chromatography using
an NS1-speciﬁc antibody. Fig. 3A depicts a typical elution curve for
sNS1 puriﬁcation and purity was analyzed by silver stain of an
SDS-PAGE gel (Fig. 3B). Supernatants collected from the 293T-Ctrl
cell line were subjected to the same puriﬁcation procedure; the
end product served as a puriﬁcation control (pCtrl) for puriﬁed
sNS1 and was used at the same volume as puriﬁed sNS1. The effect
of puriﬁed sNS1 on TLR3-mediated IFNβ promoter activation
was determined by reporter assay. After 16 h of treatment with
puriﬁed sNS1 or pCtrl, HeLa cells were stimulated with poly(I:C).
Cells pretreated with pCtrl strongly induced IFNβ promoter activity.
In contrast, cells pretreated with puriﬁed sNS1, showed a signiﬁ-
cantly diminished response to poly(I:C) stimulation (Fig. 3C).
Fig. 1. NS1 containing cell culture supernatants inhibit the TLR3 response in HeLa cells. (A) HeLa cells were transfected with an IFNβ-Luc reporter construct and a β-gal
expressing plasmid and subsequently co-cultured with either regular HeLa cells or HeLa cells harboring a WNV replicon (HeLa rep). Luc activity was determined 4 h after the
addition of pIC to the culture media and normalized to β-gal activity. Asterisks represent statistically signiﬁcant differences, determined by Student's t-test, comparing the
pIC response of HeLa:HeLa rep samples to that of HeLa:HeLa samples. (B) HeLa cells transfected with IFNβ reporter and β-gal as above were incubated for 16 h with cell
culture supernatants from either regular HeLa cells or HeLa rep cells then stimulated with pIC before Luc activity was determined. Asterisks represent statistically signiﬁcant
differences, determined by Student's t-test comparing the pIC response of HeLa rep cells to that of HeLa cells. (C) HeLa cells were incubated with cell culture supernatants
from either 293T-Ctrl or 293T-NS1 cells for 16 h. NS1 association with the cells was detected by immunoﬂuorescence of permeabilized cells using WNV MHIAF. (D) HeLa cells
were incubated with control or sNS1-containing supernatants for 16 h and extensively washed before lysis. Whole cell lysates were analyzed by immunoblot with WNV
MHIAF followed by HRP-labeled mouse antibody. (E) NS1 association with naïve cells by ﬂow cytometry. HeLa cells were incubated with control or sNS1-containing
supernatants for 6 h and 24 h either left unpermeabilized to detect NS1 on the cell surface or permeabilized prior to staining to detect internalized NS1. NS1 was detected
with an NS1-speciﬁc antibody. (F) Secreted NS1-containing cell culture supernatants inhibit the TLR3 response in HeLa cells. HeLa cells transfected with IFNβ reporter
construct and β-gal were incubated with supernatants from either 293T-Ctrl or 293T-NS1 cells for 16 h and stimulated as above. Asterisks represent statistically signiﬁcant
differences, determined by Student's t-test of sNS1-containing supernatant treated samples compared to control treated samples.
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TLR3-mediated IL-6 secretion by HeLa cells was also signiﬁcantly
inhibited by pretreatment with puriﬁed sNS1. The inhibition was
dose-dependent and statistically signiﬁcant at concentrations greater
than 1.25 μg/mL (Fig. 3D). Fig. 3E shows that signaling inhibition was
lost when sNS1 was heated to 95 1C (sNS1-heat) or upon antibody
depletion of sNS1 from supernatants (NS1 FT), demonstrated in
Fig. 3F. These data conﬁrm that the observed inhibitory effects are
sNS1-dependent.
Secreted NS1 inhibits TLR signaling in bone marrow derived primary
cells
It was of interest to determine whether sNS1 inhibits Toll-like
receptor signaling pathways other than those originating from
TLR3. We investigated the effect of sNS1 on bone marrow-derived
mouse macrophages (BMDMs) and bone marrow-derived myeloid
dendritic cells (BMDCs), two immunologically relevant cell types
that endogenously express several different TLRs. Because protein
degradation is a function of BMDMs and BMDCs, initial experi-
ments were performed to determine the pretreatment times
resulting in the highest level of intracellular sNS1 accumulation
before protein degradation is observed (data not shown). BMDCs
or BMDMs were pretreated with sNS1, heat-inactivated sNS1
(sNS1-heat), or pCtrl for 16 h. TLR3 was stimulated with poly
(I:C), TLR4 with lipopolysaccharide (LPS), and TLR7 with resiqui-
mod (R848). After 8 h of TLR stimulation, IL-6 secretion by BMDMs
was measured by ELISA. The pCtrl-treated cells and cells treated
with heat-inactivated sNS1 did secrete high levels of IL-6 in
response to stimulation by poly(I:C) and LPS. In contrast, treat-
ment with sNS1 signiﬁcantly inhibited IL-6 production after
stimulation with both poly(I:C) and LPS (Fig. 4A). BMDMs did
not respond to R848. BMDCs produced only low levels of IL-6, but
did secrete signiﬁcant levels of IL-12 in response to TLR stimula-
tion (Kawai and Akira, 2008). Therefore, TLR signaling by BMDCs
was assessed by measuring IL-12p70 secretion after 12 h of TLR
stimulation. Treatment with sNS1 resulted in diminished IL-12
production by BMDCs stimulated with poly(I:C) or LPS, and also
inhibited IL-12 secretion in response to R848 stimulation (Fig. 4B).
While sNS1-mediated signaling inhibition of all the TLRs tested in
BMDCs was statistically signiﬁcant, it should be noted that TLR3
signaling was affected more than TLR4 and TLR7 signaling. We
next examined how sNS1 treatment would affect the cytokine
response to WNV infection in primary cells. BMDMs were pre-
treated with sNS1 or pCtrl for 16 h and subsequently infected with
WNV at an MOI of 0.1. RNA was isolated 24 h after infection and
analyzed by real-time RT-PCR. Compared to pretreatment with
pCtrl, pretreatment of BMDMs with sNS1 resulted in a signiﬁcant
reduction in WNV-induced IL-6 and IFNβ transcript levels (Fig. 5A
and B). Growth of WNV was monitored on sNS1-pretreated cells to
determine if sNS1 pretreatment would inﬂuence viral replication.
Interestingly, growth of WNV on BMDMs was not affected despite
decreased cytokine transcription (Fig. 5C). The reasons for these
results are not entirely clear, however, it is possible that even the
reduced amount of cytokines induced after sNS1 pretreatment was
sufﬁcient to impair virus production to levels similar to those in
pCtrl-treated cells. Together, these results demonstrate that sNS1
not only inhibits TLR3 signaling, but also inhibits signaling from
other TLRs, although the extent of inhibition varied by TLR and by
cell type. Additionally, sNS1 pretreatment resulted in a diminished
cytokine response to virus infection.
Secreted NS1 interacts predominantly with macrophages and
dendritic cells in vivo
We were interested in examining the possibility of immune
modulation by sNS1 in vivo but wanted to ﬁrst determine the fate of
sNS1 upon introduction into mice. Secreted NS1 was delivered by
subcutaneous footpad inoculation because this is the most com-
monly used model of mosquito-delivered WNV infection. Footpad
inoculation would also allow monitoring sNS1 migration into the
popliteal lymph node (pLN), the draining lymph node of the
footpad. Thus, either 5 μg of Alexa 488 (A-488)-labeled sNS1, or
an equal volume of unincorporated A-488 dye, were injected into
the rear footpads of C57BL/6 mice. The amount of sNS1 injected was
within the range of NS1 serum concentrations previously reported
for WNV sNS1 in a mouse model (Macdonald et al., 2005) as well as
the range reported for sNS1 in dengue patients (Young et al., 2000).
The pLNs were harvested 6 h after sNS1 injection and a single cell
suspension of the lymph nodes was analyzed by ﬂow cytometry
(Fig. 6A). Analysis of the pLNs showed the A-488 unincorporated
dye did not stain any cell type appreciably, however approximately
80% of macrophages and 60% of DCs were positive for A-488 labeled
sNS1. Secreted NS1 only associated with 2% of either CD4þ or
CD8þ T cells, despite a signiﬁcantly greater number of these cells in
the draining lymph node, suggesting sNS1 preferentially binds to
macrophages and DCs.
Fig. 2. Inhibition of GAG sulfation prevents sNS1 association and restores TLR3
signaling. HeLa cells were incubated for 24 h in either DMEM or sulfate-free
medium (SF) in the absence or presence of increasing concentrations of sodium
chlorate before addition of sNS1-containing or control supernatant under the same
conditions. (A) Permeabilized cells were analyzed for sNS1 association by ﬂow
cytometry. The initial gate was set on live cells using FSC vs SSC. Cells not incubated
with sNS1 served to set the gate shown. (B) Loss of sNS1-cell interaction restores
TLR3 signaling. IL-6 was measured from HeLa cells treated as described in A and
stimulated with 20 μg/mL pIC for 8 h. Asterisks denote statistically signiﬁcant
differences between 293T-Ctrl and 293T-NS1 pretreated pIC-stimulated cells.
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Secreted NS1 inhibits the in vivo response to poly(IC:LC) stimulation
and VRP infection
Based on our ﬁndings that sNS1 associates with macrophages
and DCs, it was of interest to determine whether sNS1 would also
inhibit TLR responses in vivo. C57BL/6 mice were injected into the
rear footpad with 5 μg of either puriﬁed sNS1 or heat-inactivated
sNS1, or an equal volume of pCtrl. Six hours later, the mice were
stimulated by injection of 20 μg of poly(IC:LC) into the rear footpad.
Poly(IC:LC) (Hiltonol) is a polylysine stabilized form of poly(I:C)
reported to induce potent innate immune responses in vivo (Caskey
et al., 2011). After 16 h of poly(IC:LC) stimulation, the pLNs were
harvested and processed for total RNA extraction. Expression of IL-6
(Fig. 6B), and IFNβ (Fig. 6C) mRNA was determined by real-time
qRT-PCR. Mice pretreated with pCtrl and heat-inactivated sNS1
responded to poly(IC:LC) stimulation with upregulation of IL-6 and
IFNβ transcription. In contrast, mice pretreated with sNS1 showed
signiﬁcantly reduced cytokine transcription.
To determine the effects of sNS1 in the context of in vivo infection
we chose to use virus replicon particles (VRPs). Infection by VRPs
offers the unique opportunity to test local responses to the initial
infection without resulting in a spreading infection, the response to
which might override early inhibitory effects of sNS1. A previous
study showed upregulation of IFNβ and IL-6 transcription in the pLN
Fig. 3. Incubation with puriﬁed sNS1 inhibits TLR3 signaling in HeLa cells. (A) NS1-speciﬁc ELISA on immunoafﬁnity puriﬁcation fractions. (B) Silver stain on SDS PAGE gel of
puriﬁed sNS1, the puriﬁcation control (pCtrl) and the ﬂow through fraction during the puriﬁcation. (C) HeLa cells were transfected with IFNβ reporter construct and β-gal
expression construct and incubated with 4 μg/mL puriﬁed sNS1 or an equal volume of pCtrl for 16 h prior to stimulation with pIC. Control for these experiments was
supernatant from 293T vector control cells that underwent a puriﬁcation process identical to that of the sNS1-containing supernatants (pCtrl). Asterisks denote statistically
signiﬁcant differences between pCtrl and sNS1 pretreated pIC-stimulated cells. (D) Dose response curve. Varying concentrations of puriﬁed sNS1 or equal volume of pCtrl
was added to HeLa cells in full serum media and incubated for 16 h before 8 h of pIC treatment and subsequent IL-6 ELISA analysis of supernatants. Asterisks denote
statistically signiﬁcant differences between pCtrl and sNS1 pretreated pIC-stimulated cells. (E) IL-6 secretion was measured from pIC treated HeLa cells following incubation
with pCtrl, 5 μg/mL sNS1, 5 μg/mL sNS1-heat or equal volumes of the ﬂow through fraction generated during the puriﬁcation process for either control cell supernatant or
NS1-expressing cell supernatant. (F) Western blot conﬁrming depletion of sNS1 in the ﬂow through fraction used in (E). Asterisks denote statistically signiﬁcant differences
between pCtrl and NS1 pretreated cells, stimulated with pIC.
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24 h after footpad inoculation with WNV VRPs (Bourne et al., 2007).
These data indicate that lymphoid tissues are a signiﬁcant source
of IFN production early in WNV infection and that the footpad
inoculation model is suitable for monitoring the early innate
responses to VRP infection. Six hours after footpad injection of
sNS1 or heat-inactivated sNS1, mice were inoculated with WNV
VRPs via the footpad and 16 h later, pLNs were harvested and
processed for real-time qRT-PCR analysis. WNV VRP-induced tran-
scriptional upregulation of both IL-6 and IFNβ was signiﬁcantly
diminished in mice pretreated with sNS1 as compared to mice
pretreated with heat-inactivated sNS1 (Fig. 7A and B). Analysis of
genome copy numbers shows replication was not affected by the
sNS1 pretreatment, in agreement with our in vitro replication data
(Fig. 7C).
Discussion
Based on our previous studies regarding the ability of
intracellularly-expressed WNV NS1 to inhibit TLR3 signaling, we
explored the possibility that the secreted form of NS1 would also
inhibit signal transduction in naïve cells. This hypothesis was
initially tested using sNS1-containing supernatants from WNV
replicon-bearing cells (HeLa rep) or cells engineered to express
NS1 (293T-NS1 cells). Our data show the supernatants from these
cells lines were able to inhibit TLR3 signaling in naïve HeLa cells.
Additionally, puriﬁed sNS1 inhibited TLR3 signaling in a dose-
dependent manner and depletion of sNS1 from the culture super-
natants or heat-inactivation restored TLR3 signaling in naïve HeLa
cells. Our data shows sNS1 explicitly associates with naïve cells by
binding to the cell surface and being internalized. It was pre-
viously demonstrated that cell-binding by dengue sNS1 and WNV
sNS1 can be prevented by sodium chlorate pretreatment to inhibit
the sulfation of glycosaminoglycans expressed on the cell surface
(Avirutnan et al., 2007; Youn et al., 2010). In agreement with these
reports, our data show that binding of sNS1 can be inhibited by
sodium chlorate pretreatment of HeLa cells. We show that by
preventing binding of sNS1 to naïve cells, TLR3 signaling is
restored. Collectively, our data clearly indicate that the inhibitory
effect is mediated directly by sNS1.
Baronti et al. have reported that the NS1 proteins of several
different ﬂaviviruses, including WNV, do not inhibit TLR3 signaling
Fig. 4. Puriﬁed sNS1 inhibits TLR signaling in BMDMs and BMDCs. (A) BMDMs
derived from C57BL/6 mice were incubated for 16 h with 5 μg/mL sNS1 or sNS1-
heat, or pCtrl followed by 8 h pIC treatment at 5 μg/mL. IL-6 release was measured
by ELISA. (B) Myeloid DCs derived from WT C57BL/6 mice were incubated with
5 μg/mL sNS1 or controls for 16 h and stimulated with 10 μg/mL pIC for 12 h. IL-
12p70 release into supernatants was determined by ELISA. Control for these
experiments was supernatant from 293T vector control cells that underwent an
identical puriﬁcation process as NS1 supernatants and was added at the same
volume as sNS1. Asterisks denote statistically signiﬁcant differences between sNS1-
heat and sNS1 pretreated -stimulated cells.
Fig. 5. Secreted NS1 modulates cytokine production during WNV infection.
(A) BMDMs were pretreated with either puriﬁcation control or puriﬁed sNS1 for
16 h, followed by infection with WNV at an MOI of 0.1 for 24 h. IL-6 mRNA levels
were measured by real-time qRT-PCR. (B) Cells were treated and infected as in
(A) and IFNβ mRNA levels were measured by real-time qRT-PCR. Asterisks denote
statistically signiﬁcant differences between Ctrl and NS1 pretreated WNV-stimu-
lated cells as determined by Student's t-test. (C) BMDMs pretreated with either the
puriﬁcation control or puriﬁed sNS1 for 16 h were infected with WNV at an MOI of
0.01 and virus production was monitored at the indicated timepoints over 72 h by
titration of virus containing supernatants on Vero cells.
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(Baronti et al., 2010). It is not clear why the results of these authors
differ so signiﬁcantly from ours, however in their study the
authors resorted to overexpressing IRF3 in order to detect TLR3-
induced transcriptional activation of IFNβ and RT-PCR was used as
the main readout for TLR signaling. We determined previously that
HeLa cells fail to produce signiﬁcant levels of IFN-β transcript and
protein following pIC stimulation alone, which may explain these
conﬂicting results (Wilson et al., 2008). For our past and present
studies, TLR3 signaling was determined using a combination of
Fig. 6. Secreted NS1 associates with innate cells and inhibits PRR signaling in vivo.
(A) 5 μg of Alexa 488 ﬂuorescently labeled puriﬁed sNS1 protein were injected into
mice via the rear footpad, After 6 h draining lymph nodes were harvested and
analyzed for cell type speciﬁc markers and NS1 ﬂuorescence. The percentage of NS1
positive cells in the entire cell type population is shown. ((B) and (C)) C57BL/6 mice
were injected with 5 μg of puriﬁed sNS1 into each rear footpad. After 6 h the mice
were stimulated by injection of 20 μg of Poly(IC:LC) per footpad. After 16 h pLNs
were harvested and pooled per mouse before RNA extraction and cDNA synthesis.
IFNβ mRNA levels (B) and IL-6 mRNA levels (C) were determined by real-time qRT-
PCR. Controls for the experiments in (B) and (C) were heat-inactivated sNS1 and the
puriﬁcation control.
Fig. 7. Secreted NS1 diminishes the response to WNV VRP infection in vivo. C57BL/
6 mice were pre-injected with puriﬁed sNS1 or sNS1-heat as described above and
stimulated by injection of 1105 iu WNV VRPs into each footpad. PLNs were
collected and processed as described in Fig. 6. IL-6 mRNA (A) and IFNβ mRNA
(B) and WNV RNA levels (C) were analyzed by real-time qRT-PCR. A representative
experiment out of three independent studies is shown.
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reporter assays, real-time qRT-PCR, and endogenous cytokine
production and overexpression of signaling intermediates was
not required to detect activation ((Scholle and Mason, 2005;
Wilson et al., 2008) and this report). We also demonstrate that
sNS1-mediated inhibition of TLR3 and other TLRs is not limited to
HeLa cells, but extends to more immunologically relevant cell types,
such as macrophages and dendritic cells, and can be demonstrated
in vivo.
Flaviviruses are recognized by different pattern recognition
receptors during infection. Using primary cells, our data demon-
strate the ability of sNS1 to inhibit signaling by multiple TLRs as
well as reduce the IL-6 and IFNβ responses to WNV infection. in vivo
we show a diminished response to both poly(IC:LC) stimulation and
VRP infection after sNS1 pretreatment. Several studies have demon-
strated that RIG-I and Mda-5 are important in early the recognition
and response to ﬂavivirus infection (Fredericksen and Gale, 2006;
Fredericksen et al., 2004; Loo et al., 2008). Our data showed
treatment with sNS1 diminished the early IL-6 and IFNβ responses
to WNV infection in BMDMs and to VRP infection in mice. There-
fore, our results suggest that sNS1 may have additional functions in
inhibiting signaling events originating from PRRs other than TLRs.
Although our data show a strong inhibitory effect on the
immune response to WNV infection, the sNS1-mediated decrease
in cytokine production did not translate to increased viral growth.
At this point, it is unclear why no enhancement of virus growth
was observed after sNS1 pretreatment. However, the sNS1 treat-
ment did not completely ablate IFNβ production in response to
WNV infection, and as we have no evidence to suggest that sNS1
inhibits signaling through the type I IFN receptor, and the auto-
crine effects of residual IFNβ production may have been sufﬁcient
to stimulate the IFN ampliﬁcation loop, limiting spread of the
virus. To directly study the impact of sNS1 on virus replication and
viral spread in an animal model would require infection with live
WNV. However, these studies are complicated by the multifunc-
tional nature of NS1. Secreted NS1 has a number of well-described
immunomodulatory effects on the lectin and alternative pathways
of the complement system (Avirutnan et al., 2010, 2011; Chung et
al., 2006; Fuchs et al., 2010, 2011). Therefore, any observed effects
of sNS1 on the pathogenesis of live virus infection could not be
attributed directly to PRR inhibition.
The cytokine response to infection is important in aspects of
viral pathogenesis beyond the direct control of pathogen prolif-
eration, including cell recruitment and the orchestration of B cell
and T cell responses. In the pLN, sNS1 was found to associate
predominantly with macrophages and DCs, the primary cell types
involved in innate immune responses and antigen presentation.
This suggests that sNS1 could potentially inﬂuence the develop-
ment of an adaptive immune response to WNV infection. Indeed, a
role for TLR3 in the development of the humoral response to WNV
single-cycle infectious particles, called RepliVAX WN was recently
described (Xia et al., 2013). Using a mouse model, the authors
show TLR3-deﬁciency results in a short lived WNV-speciﬁc anti-
body response after inoculation with RepliVAX WN, and report
that TLR3 is important in the maintenance of germinal centers
(GCs), the sites of antigen-speciﬁc B cell proliferation and matura-
tion. This study also shows impaired B cell activation and hindered
development of GCs as well as a diminished memory B cell
response in MyD88/ mice. MyD88 is the adaptor molecule in
the TLR7 signaling cascade. TLR7 is also important in the immune
response to WNV, and in fact, plays a role in the recognition of
ﬂaviviruses by plasmacytoid dendritic cells, triggering the early
IFNα response and contributing to immune cell homing to sites of
infection. (Diebold et al., 2004; Lund et al., 2004; Silva et al., 2007;
Town et al., 2009; Wang et al., 2006; Welte et al., 2009).
To our knowledge, this report is the ﬁrst to describe PRR
signaling inhibition by a secreted protein from an RNA virus. PRR
inhibition has been described for other WNV proteins. Whether
the sNS1 proteins of other ﬂaviviruses have immunomodulatory
properties similar to that of WNV sNS1 remains an important
question. Another WNV protein, the structural protein, E, is able to
subvert dsRNA-mediated signaling, however this is only true of the
E protein of mosquito cell origin and not true of E protein
generated in mammalian cells (Arjona et al., 2007). Therefore,
TLR3 signaling inhibition by the E protein would occur only during
the very ﬁrst infection cycle. The NS1 protein used for our studies
was secreted by mammalian cells and therefore our in vitro and
in vivo data indicate immune modulation by sNS1 likely occurs
throughout infection, suggesting sNS1 could inﬂuence the adap-
tive immune response to infection.
In summary, our ﬁndings provide novel evidence of PRR
signaling inhibition by the secreted form of WNV NS1. Our data
show targeting of DCs and macrophages by sNS1 in vivo and our
in vitro studies show active repression of signaling by these cell
types. As DCs and macrophages link the innate and adaptive
immune responses, additional studies aimed at characterizing
the effect of sNS1 on the adaptive immune response are essential.
Our data show immune suppression by sNS1 in vivo, however,
further research into the mechanisms used by WNV sNS1 to
undermine the host antiviral response and how these immune
evasion strategies inﬂuence viral pathogenesis is necessary. These
studies will provide information critical to the development of
treatment strategies and vaccination programs that control WNV
infection. The use of vaccine adjuvants can enhance immunity to
virus infection and there is evidence that TLR ligands can function
as effective vaccine adjuvants (Duthie et al., 2011). Information as
to the mechanisms of NS1-mediated TLR-signaling inhibition
would contribute to the design of adjuvants that will successfully
bolster immunity to WNV and suppress infection. Our data
describes a novel function of WNV NS1, a protein with a diverse
array of immunomodulatory actions, that contribute to viral
pathogenesis and thus the multifunctional nature of this protein
necessitates further study.
Materials and methods
Cell lines
HeLa cells were grown in DMEM (Cellgro) supplemented with
10% HyClone fetal bovine serum (Cellgro), 1% antibiotics, and
20 mg/mL gentamicin. Human Embryonic Kidney (HEK 293T) cells
were transduced with an NS1-His encoding recombinant lenti-
virus (pLEX-NS1) or an empty vector control lentivirus (pLEX-Ctrl).
The pLEX-NS1 and pLEX-Ctrl were packaged into VSV-G pseudo-
typed, replication defective, lentivirus particles through co-
transfection of HEK 293T cells with vector, packaging (pREV and
pMDLg), and envelope (pVSV-G) plasmids. Lentivirus-containing
supernatants were harvested and clariﬁed 40 h post-transfection.
The 293T cells were transduced with pLEX-NS1 or pLEX-Ctrl
lentivirus for 24 h in the presence of 8 μg/mL polybrene. Trans-
duced cells were selected by puromycin treatment at 4 μg/mL as a
pool. The resulting cell lines are termed 293T-NS1 and 293T-Ctrl.
293T-NS1 cells were used in the production of sNS1 containing
supernatants used for experiments and for sNS1 puriﬁcation.
293T-Ctrl cell supernatants were treated identically to NS1-
containing supernatants during collection and puriﬁcation.
Primary cells
Wild-type C57BL/6 mouse femurs were collected and bone
marrow was harvested per standard protocols. Macrophages were
grown for 7 days in DMEM containing 10% fetal bovine serum,
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1% non-essential amino acids, 1% antibiotics and differentiated in
the presence of M-CSF. Myeloid dendritic cells were grown for 10
days in RPMI containing 10% fetal bovine serum, 1% antibiotics,
55 μM beta-mercaptoethanol and differentiated in the presence of
IL-4.
Puriﬁcation of NS1
A mouse monoclonal antibody to JEV NS1 (clone 6H4, a kind
gift from Dr. Eji Konishi, Osaka University) was coupled to CnBr
beads overnight at 4 1C. The beads were packed into a column and
prepared with oscillating pH washes followed by two additional
low pH washes and two high pH washes. Clariﬁed NS1 containing
cell supernatant was applied to the column. The beads were then
washed at neutral pH and protein was eluted in 0.5 mL fractions
with a high pH solution. The fractions were immediately neutra-
lized with 1 M Tris buffer and assayed by ELISA for NS1 content.
NS1 ELISA was performed by coating Immulon 2HB plates
(Thermo) with the eluted fractions at 4 1C for 12–16 h followed
by detection with the anti-JE NS1 antibody and HRP-labeled
mouse secondary antibody. Color was developed with 3,30,5,50-
tetramethylbenzidine (TMB) substrate and the reaction was
stopped with 2N H2SO4. Fractions positive for NS1 by ELISA were
run on 4–12% NuPage protein gels and subjected to silver stain
(BioRad) to ensure purity. Pure NS1 fractions were then pooled
and dialyzed against PBS overnight at 4 1C. The amount of protein
present in the samples after dialysis was determined using a
protein assay kit (Bio-Rad). Supernatants from the 293T-Ctrl cell
line were subjected to the same puriﬁcation process and the
fractions collected were dialyzed against PBS and used as a
puriﬁcation control (pCtrl).
Immunodepletion of NS1
During sNS1 puriﬁcation, ﬂow-through samples were collected
from the immunoafﬁnity column after the application of the NS1-
containing supernatants. Depleted supernatant samples were
analyzed by Western blot to conﬁrm the absence of NS1. Samples
were dialyzed against PBS before use in cell culture assays.
Reporter assays
Reporter assays using the luciferase (Luc) reporter gene under
control of the IFN-β promoter (IFN-β pGL3; a gift from J. Hiscott)
have been described previously (Scholle and Mason, 2005; Wilson
et al., 2008). Brieﬂy, 150 ng each of IFN-β pGL3 and pCMV β-
galactosidase (β-Gal) (Invitrogen) were co-transfected into HeLa
cells, using the TransIT-LT1transfection reagent (Mirus). At 4 h
post-transfection, clariﬁed NS1-containing supernatant or clariﬁed
control supernatant was added to the cells. For experiments using
puriﬁed sNS1, the appropriate concentration of sNS1, or an equal
volume of pCtrl, was prepared in full serum media. Heat-
inactivation of sNS1 was achieved by heating the sample at 95 1C
for 1 h. After 16 h cells were either left untreated or were
stimulated by adding 20 mg/mL poly(I:C) (pIC; Calbiochem) to the
culture media and incubating for 4 h. Following treatment, cells
were lysed in reporter lysis buffer (0.1% TritonX-100, 10% glycerol,
2 mM Dithiothreitol, 2 mM trans 1,2 diaminocyclohexane-NNNN
acetic acid, and 25 mM Tris phosphate) and assayed for Luc and
β-Gal activities using a Promega Luc assay system and an ONPG
(o-nitrophenyl-β-D-galactopyranoside)-based β-Gal assay. β-Gal
activity was used to normalize the Luciferase data for all experi-
ments. All data are expressed as relative light units/mU of β-Gal
activity.
Western blot analysis
Protein extracts were prepared in cell lysis buffer (300 mM
NaCl, 50 mM Tris–HCl, 0.1% Triton X-100, pH 7.6). Followinga10-
min incubation on ice, lysates were clariﬁed by centrifugation,
and protein concentrations were determined using a detergent-
compatible protein assay kit (Bio-Rad). Equal amounts of protein
were electrophoretically separated on 4 to 12% Nu-PAGE gels
(Invitrogen) and electroblotted onto polyvinylidenediﬂuoride
membranes (Immobilon-P transfer membrane; Millipore). Follow-
ing a blocking step with Tris-buffered saline containing 0.1%
Tween-20 and 5% dry milk, NS1 was detected using a WNV-
speciﬁc mouse hyperimmune ascitic ﬂuid [MHIAF] as the primary
antibody (Scholle and Mason, 2005), followed by a horseradish
peroxidase (HRP)-conjugated secondary antibody (KPL). Bound
HRP was visualized with an Immunocruz ECL kit (Santa Cruz).
Membranes were stripped and re-probed with a mouse anti-β-
actin antibody (Sigma-Aldrich) as a loading control.
Immunoﬂuorescence
HeLa cells were seeded onto LabTek (Nunc) chamber slides and
incubated with supernatants from NS1-expressing cells or control
cells for 16 h at which time the slide was prepared for indirect
immunoﬂuorescence analysis (IFA) for identiﬁcation of NS1 protein.
Brieﬂy, cells were washed with PBS, ﬁxed in 4%paraformaldehyde,
permeabilized with 0.1% Triton X-100, and blocked (2% bovine
serum albumin, 5% normal horse serum, and 10 mM glycine in
PBS). The cells were incubated with WNV MHIAF as the primary
antibody, followed by incubation with AlexaFluor 568-conjugated
anti-mouse antibody (Invitrogen) and then analyzed for presence of
NS1 by immunoﬂuorescence using a Zeiss Axioskop 2 microscope.
ELISA
Levels of IL-6 or IL-12p70 in cell culture supernatants were
determined by enzyme-linked immunosorbent assay (ELISA)
(e-Bioscience) according to the manufacturer's speciﬁcations.
Analysis of sNS1-cell binding to HeLa cells
HeLa cells were incubated in the presence of sNS1 for indicated
times, the cells were then washed with PBS before ﬁxing and
permeabilizing on ice for 20 min (BD Cytoﬁx/Cytoperm kit) or left
unpermeabilized and ﬁxed with 4% paraformaldehyde for 5 min
on ice. Cells were incubated with a primary antibody generated
against the NS1 protein of Japanese Encephalitis virus and then an
Alexaﬂuor A488-tagged secondary antibody. Analysis was per-
formed on the Accuri C6 ﬂow cytometer according to standard
protocol.
Real-time qRT-PCR
Total RNA was extracted using a Qiagen RNeasy kit with DNase
treatment according to the manufacturer's speciﬁcations. Reverse
transcription (RT) was carried out with the ImProm II RT kit (Promega)
using oligodT as primer. Random hexamer was used as primer for NS5
experiments. Real-time PCR analysis was carried out using the
SensiMix SYBR & Fluorescein kit (BioLine) and the following primers;
mGAPDH 50-TGCCCAGAACATCATCCCTG-30 and 50-ATCCACGACGGACA-
CATTGG-30, mIL-6 50-GACTTCACAGAGGATACCACTCC-30 and 50-TT-
CTGCAAGTGCATCATCGGT-30,mIFNβ 50-GGAGATGACGGAGAAGATGC-
30 and 50-CCCAGTGCTGGAGAAATTGT-30, Kunjin NS5 50-GAGTCCAA-
GAAGTCAGAGGGTACA-30 and 50-CCACTCTTCATGGTGACAATGTTCC-30.
Reactions were set up in 96-well PCR plates (Genesee). Ampliﬁcations
were carried out for 50 cycles, followed by a melt curve analysis of
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resulting products to conﬁrm the speciﬁcity of the reactions. To
construct standard curves, total RNA was isolated from the cells, and
300- to 600-bp fragments of the gene of interest encompassing the
real-time PCR primer binding sites, were ampliﬁed by RT-PCR using
the appropriate primer sets. PCR fragments were gel puriﬁed and
quantiﬁed, and the copy number was calculated. Serial 10-fold
dilutions were prepared for to create standard curves for real-time
qPCR. All data are expressed as the ratio of copy numbers of target
gene per 103 or 104copies of GAPDH as indicated.
VRP production and puriﬁcation
RepliVAX WN contains a deletion of the capsid protein and is
only able to replicate for a single infection cycle. RepliVAX can be
packaged into infectious particles by supplying the missing capsid
protein in trans (Mason et al., 2006). To produce high titer stocks
for in vivo studies, BHK (VEErep/Pac-Ubi-Cn) cells expressing the
WNV capsid protein from a Venezuelan encephalitis virus replicon
were inoculated with RepliVAX WN VRPs (Mason et al., 2006) at
an MOI of 0.05 and supernatants were harvested 96 hpi. The
supernatants were clariﬁed and then concentrated over a 100,000
kilodalton (kda) cutoff centrifugal ﬁlter at 1500g. The concentrate
was applied to a 10–40% sucrose gradient and centrifuged at
35,000 rpm at 4 1C for 2.5 h. The fractions containing infectious
particles were collected and washed three times with L15 medium
over a centrifugal ﬁlter to remove residual sucrose. The ﬁnal
concentrate was resuspended in L15 medium containing 10 mM
HEPES and 0.1% FBS. VRP titers were determined on Vero cells by
immunostain against WNV-speciﬁc antigen and reported as infec-
tious units per mL (iu/mL).
In vivo experiments
C57BL/6 mice were obtained from Charles River laboratories
and housed under speciﬁc-pathogen-free conditions in the Biolo-
gical Resources Facility at NCSU. All procedures were conducted in
accordance with the NCSU Institutional Animal Care and Use
Committee. Eight to twelve week old female C57/BL6 mice were
injected with 5 μg of puriﬁed sNS1 into both rear footpads. After
6 h, mice were stimulated by injection of 20 μg poly(IC:LC)
(Hiltonol, Oncovir), PBS control, or 1105 iu puriﬁed RepliVAX
VRPs into each footpad. Draining lymph nodes were harvested at
16 h post stimulation and processed for qRT-PCR analysis.
Secreted NS1-cell association in draining lymph nodes
Puriﬁed sNS1 was labeled with Alexaﬂuor 488 using an
Invitrogen labeling kit according to the manufacturer's instruc-
tions. Brieﬂy, sNS1 (1 mg/mL) was incubated with ﬂuorescent dye
for 1 h at RT. The labeled sNS1 was separated from the unin-
corporated dye by running it through a column packed with the
provided puriﬁcation resin. The ﬁnal puriﬁed protein was resus-
pended in PBS and quantiﬁed prior to use. The unincorporated
dye was used as a negative control for the injection experiments.
Mice were injected with 5 µg of Alexa488 labeled sNS1 into the
rear footpad. After 6 h, pLN from pairs of mice were pooled,
homogenized, and passed through a cell strainer to generate
single cell suspensions. Cells were washed and resuspended in
PBSþ1% FBS before incubation with anti-CD16/CD32 (BD Phar-
mingen) to block Fc receptors. Cells were then stained with
antibodies speciﬁc to CD3, CD8, CD4 (T cells), CD11c (DCs),
CD335 (NK cells), and F4/80 (macrophages). Antibodies were
purchased from eBiosciences, BD Pharmingen, or Biolegend. After
cell surface staining, cells were ﬁxed and permeabilized to detect
sNS1–488. The cells were washed three times and resuspended in
300 μL of PBSþ1% FBS and samples were subsequently analyzed
by ﬂow cytometry on a C6 Accuri cytometer using Accuri CFlow
software.
Statistical analysis
Statistical analysis was performed using Student's t-test.
P values below 0.05 were considered signiﬁcant.
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